Advertisement

Topics

Auven Therapeutics Company Profile

13:29 EDT 22nd May 2017 | BioPortfolio

Auven Therapeutics is a private equity company focused on the healthcare industry.

The Company’s strategy is to acquire controlling ownership in promising therapeutic products or platforms. The value of these therapeutic assets is then significantly enhanced by global development programs prior to selling them as clinically and commercially validated products to established pharmaceutical companies.

Auven Therapeutics has built a diversified portfolio of biologic and small molecule therapeutic candidates for a wide range of therapeutic indications. The Company’s existing pipeline addresses critical unmet medical needs in cancer, ophthalmic conditions, women’s health and orphan diseases.

It has ownership of or a controlling interest in the therapeutic assets of ADC Therapeutics, Spirogen, Resolvyx and Kiacta, and a minority investment in Kolltan and Sprout Pharmaceuticals.

Founded in 2007 by industry veterans Stephen Evans-Freke and Dr. Peter B. Corr, Auven Therapeutics Management L.L.L.P. is an investment advisor with its principal place of business in the US Virgin Islands. It manages Auven Therapeutics Holdings L.P., a private equity fund, which has its registered office and principal place of business in the British Virgin Islands. Auven Therapeutics Development, the operating company of Auven Therapeutics Holdings L.P. manages drug development from its bases in Lausanne, Switzerland, New York, USA and Hamilton, Bermuda.

Location

6501 Redhook Plaza, Suite 201
St. Thomas
USVI
00802
USVI

Contact

Phone: +1-340-779-6908 (phone)
Fax: +1-340-714-5192 (fax)
Email: info@auventx.com


News Articles [2038 Associated News Articles listed on BioPortfolio]

After Failed Phase III, Auven Therapeutics (previously known as Celtic Therapeutics Management L.L.L.P.) to Terminate the KIACTA Program

  Life Sciences Jobs   ...

BRIEF-Bellus Health provides update on pipeline

* Auven Therapeutics has decided to terminate Kiacta program for treatment of AA Amyloidosis

Ep. 34: Versant closes oversubscribed sixth healthcare-focused fund

Versant Ventures closes its newest fund, a new stem cell company is born in the MaRs Discovery District and Auven Therapeutics official pulls the plug on the KIACTA™ AA amyloidosis program. We have ...

After Failed Phase III, Auven to Terminate the KIACTA Program

  Life Sciences Jobs   ...

Sun Pharma continues rapid expansion in eye care technologies

Sun Pharmaceutical Industries in Mumbai, India, continues its rapid expansion into the ocular space with the announced acquisition of Ocular Technologies, whose lead candidate is the eye drop Seciera ...

BELLUS Health’s partner terminates KIACTA™ program for the treatment of AA amyloidosis

LAVAL, QC – As part of an update on projects in its pipeline, BELLUS Health reports its partner Auven Therapeutics, who acquired the rights to KIACTA™ from the company in 2010, has decided to ...

Auven Therapeutics Management LLLP Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 23022017] Prices from USD $250

SummaryAuven Therapeutics Management L.L.L.PAuven Therapeutics Management, previously known as Celtic Therapeutics Management L.L.P. is a private equity firm that invests in novel therapeutic product ...

Auven Therapeutics Management LLLP Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 10032017] Prices from USD $250

SummaryAuven Therapeutics Management L.L.L.PAuven Therapeutics Management, previously known as Celtic Therapeutics Management L.L.P. is a private equity firm that invests in novel therapeutic product ...

Clinical Trials [108 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1115 Associated Companies listed on BioPortfolio]

Auven Therapeutics

Auven Therapeutics is a private equity company focused on the healthcare industry. The Company’s strategy is to acquire controlling ownership in promising therapeutic products or platforms. ...

Auven Therapeutics

Auven Therapeutics is a private equity company focused on the healthcare industry. The Company’s strategy is to acquire controlling ownership in promising therapeutic products or platforms. ...

ADC Therapeutics Sarl

ADC Therapeutics (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cance...

ADC Therapeutics

ADC Therapeutics sarl (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Auven Therapeutics" on BioPortfolio

We have published hundreds of Auven Therapeutics news stories on BioPortfolio along with dozens of Auven Therapeutics Clinical Trials and PubMed Articles about Auven Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Auven Therapeutics Companies in our database. You can also find out about relevant Auven Therapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...


Corporate Database Quicklinks



Searches Linking to this Company Record